Dianthus Therapeutics, Inc. (DNTH)Healthcare | Biotechnology | New York, United States | NasdaqCM
91.92 USD
-1.34
(-1.437%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★★ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:30 a.m. EDT
While the fundamentals deteriorate severely with -78.6% revenue growth and negative cash flow, the risk-reward is compelling due to the wide safety margin. The stock is up 33% year-over-year, yet analysts see a massive runway to $125-$200 based on potential FDA approvals. The options market is screaming aggression rather than fear; with 99.9% of the implicit capital flow tilted into calls, the market believes the downside is priced in at current levels ($79 low). With a beta of only 0.21 (decoupling from market risk), this is a high-conviction momentum play on a potential catalyst, not this earnings report. If the clinical data is promising, the stock could run independently of the S&P; if it fails, the wrecking ball is already lobbed. This is for the bulls betting on the next big headline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.292235 |
| MSTL | 0.302718 |
| AutoARIMA | 0.313055 |
| AutoETS | 0.313061 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 41.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.048 |
| Excess Kurtosis | -1.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.281 |
| Revenue per Share | 0.053 |
| Market Cap | 5,004,931,072 |
| Forward P/E | -17.97 |
| Beta | 0.21 |
| Website | https://dianthustx.com |
As of April 19, 2026, 12:30 a.m. EDT: Options activity shows a massive bullish skew. Speculators are heavily positioning calls, with 93.2% of total option volume going to calls (541 vs 38). There is significant Open Interest at near-term strikes (e.g., 65/90 May Calls, 75/100 Aug Calls) suggesting a target range of 75-100, well above the current price. Conversely, put activity is negligible (mostly deep OTM in 2027), indicating speculators are not hedging for downside moves but are almost exclusively betting on upward momentum.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.2030177 |
| Address1 | 7 Times Square |
| Address2 | 43rd Floor |
| All Time High | 336.0 |
| All Time Low | 5.12 |
| Ask | 92.42 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 669,980 |
| Average Daily Volume3 Month | 1,055,209 |
| Average Volume | 1,055,209 |
| Average Volume10Days | 669,980 |
| Beta | 0.212 |
| Bid | 91.51 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 11.415 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 91.92 |
| Current Ratio | 13.323 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 93.5399 |
| Day Low | 91.1 |
| Debt To Equity | 0.281 |
| Display Name | Dianthus Therapeutics |
| Earnings Timestamp | 1,773,059,400 |
| Earnings Timestamp End | 1,778,502,600 |
| Earnings Timestamp Start | 1,778,502,600 |
| Ebitda | -177,822,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -20.722 |
| Enterprise To Revenue | 1,809.86 |
| Enterprise Value | 3,684,873,984 |
| Eps Current Year | -4.65429 |
| Eps Forward | -5.11429 |
| Eps Trailing Twelve Months | -4.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 71.962 |
| Fifty Day Average Change | 19.958 |
| Fifty Day Average Change Percent | 0.27734083 |
| Fifty Two Week Change Percent | 320.30176 |
| Fifty Two Week High | 96.5 |
| Fifty Two Week High Change | -4.580002 |
| Fifty Two Week High Change Percent | -0.04746116 |
| Fifty Two Week Low | 16.64 |
| Fifty Two Week Low Change | 75.28 |
| Fifty Two Week Low Change Percent | 4.524039 |
| Fifty Two Week Range | 16.64 - 96.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,587,800,000 |
| Float Shares | 41,979,379 |
| Forward Eps | -5.11429 |
| Forward P E | -17.973167 |
| Free Cashflow | -75,447,128 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 92 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 2,036,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0012800001 |
| Held Percent Institutions | 0.9576 |
| Implied Shares Outstanding | 54,448,771 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. |
| Long Name | Dianthus Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,004,931,072 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_631649032 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -162,336,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,003,297,567 |
| Number Of Analyst Opinions | 13 |
| Open | 93.0 |
| Operating Cashflow | -129,060,000 |
| Operating Margins | -244.86267 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 929 999 4055 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 91.92 |
| Pre Market Time | 1,776,769,405 |
| Previous Close | 93.26 |
| Price Eps Current Year | -19.74952 |
| Price Hint | 2 |
| Price To Book | 8.052563 |
| Price To Sales Trailing12 Months | 2,458.2175 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.157 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -1.34 |
| Regular Market Change Percent | -1.43685 |
| Regular Market Day High | 93.5399 |
| Regular Market Day Low | 91.1 |
| Regular Market Day Range | 91.1 - 93.5399 |
| Regular Market Open | 93.0 |
| Regular Market Previous Close | 93.26 |
| Regular Market Price | 91.92 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 526,956 |
| Return On Assets | -0.24577999 |
| Return On Equity | -0.38382998 |
| Revenue Growth | -0.786 |
| Revenue Per Share | 0.053 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,448,771 |
| Shares Percent Shares Out | 0.1666 |
| Shares Short | 9,069,811 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,893,078 |
| Short Name | Dianthus Therapeutics, Inc. |
| Short Percent Of Float | 0.1919 |
| Short Ratio | 5.73 |
| Source Interval | 15 |
| State | NY |
| Symbol | DNTH |
| Target High Price | 200.0 |
| Target Low Price | 98.0 |
| Target Mean Price | 125.46154 |
| Target Median Price | 123.0 |
| Total Cash | 404,295,008 |
| Total Cash Per Share | 9.091 |
| Total Debt | 1,386,000 |
| Total Revenue | 2,036,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 43.91455 |
| Two Hundred Day Average Change | 48.005447 |
| Two Hundred Day Average Change Percent | 1.0931559 |
| Type Disp | Equity |
| Volume | 526,956 |
| Website | https://dianthustx.com |
| Zip | 10,036 |